About Us

Who we are

Outset Medical is changing dialysis – one of the largest, most expensive, and stagnant areas of healthcare. Headquartered in San Jose, California, Outset operates across the United States and manufactures in North America. Our team is innovative, talented, and growing quickly. Learn about careers at Outset.

What we do

We are focused on creating change, driving widespread adoption of new technology, and delivering on the promise of an improved experience for patients and lower cost of care for healthcare providers.

Why we do it

We are fueled by the opportunity to give people their lives back.

When we succeed, patients will be able to fit dialysis into their life instead of fitting their life around dialysis. They will ultimately determine when, where, and how they dialyze.

Evolution of Outset

How did we get here? A brief timeline of company milestones.

2010

HD+ is officially funded
2013

First human treatments on Tablo^® in Mexico City
2014

FDA clearance for acute and chronic use, and we gain a CE Mark
2015

HD+ becomes Outset Medical
2016

2nd generation of Tablo is initiated; home clinical trial begins
2017

First use of Tablo in the acute setting at Cleveland Clinic
2018

Tablo launches commercially
2019

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief
2020

FDA clearance for home use; Outset goes public, listed on NASDAQ
2021

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report
2022

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list
Present Day

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

fast-company-best-workplaces-for-innovators-2023

Leadership

Advisors

Luis Alvarez

Read bio

Dr. Alvarez serves as Outset’s Chief Technology and Innovation Advisor, and is currently the Chair of Nephrology at the Palo Alto Medical Foundation, Sutter Health. Following his doctoral work in biophysics, he worked in the pharmaceutical and device industries. A former advisor to the Stanford Biodesign Department, Dr. Alvarez remains committed to the application of industrial continuous quality improvement concepts to the field of nephrology, including transformation of the acute renal failure care model both in the intensive unit and sub-acute hospital settings. In this capacity he also serves as a consultant to Satellite Dialysis acute care services. In addition, Dr. Alvarez works as a Medical Director for Satellite Dialysis and Wellbound Home Dialysis where he is active on the Medical Policy Committee. While maintaining a clinical practice, Dr. Alvarez devotes his time at the Palo Alto Medical Foundation working on integration of clinical services across divisions with the formation of medical service lines and
development of shared risk models of payment reform.

Glenn Chertow

MD MPH

Read bio

Dr. Chertow is the Norman S. Coplon/ Satellite Healthcare Professor of Medicine and Chief, Division of Nephrology at Stanford School of Medicine. His research interests are focused on epidemiology, health services research, and clinical trials in acute and chronic kidney disease. Dr. Chertow is involved in research sponsored by the National Institutes of Health and has written numerous papers on end-stage renal disease, acute renal failure, nutrition, mineral metabolism, and the costs and outcomes of dialysis therapy. He serves on the Board of Directors for Satellite Healthcare, Inc. and on the Scientific Advisory Board of DaVita Clinical Research. He is Co-Editor of Brenner and Rector’s The Kidney, a leading nephrology textbook. He also serves on the editorial boards of the Journal of the American Society of Nephrology (JASN) and Clinical Journal of the American Society of Nephrology (CJASN). He has served as an Advisor to MedPAC, for issues related to dialysis care. Dr. Chertow has designed and/ or monitored several NIH- and industry-sponsored cohort studies and clinical trials in kidney disease, including CRIC, ATN, FHN, DAC, SPRINT, TREAT, ADVANCE and EVOLVE. In addition to his research and teaching activities, Dr. Chertow has an active clinical practice focused on inpatient and outpatient nephrology care.

Sarah Prichard

MD FRCP(C)

Read bio

Dr. Prichard has had an academic career at McGill University, Montreal Canada, followed by a career in industry at Baxter Healthcare. Currently, she serves on various corporate boards, on Scientific Advisory Boards and as a consultant. Dr. Prichard received her MD from Queens University at Kingston and then completed her training in Internal Medicine and Nephrology at McGill University. She joined the faculty of McGill University in 1979 and remained there until 2005. At McGill she was a Professor of Medicine, served as Associate Dean for the Faculty of Medicine and became President of the Canadian Society of Nephrology (1997-2000) and the International Society for Peritoneal Dialysis (2001-2004). She published and taught widely with a focus on peritoneal dialysis and cardiovascular disease. In 2005, Dr. Prichard was recruited to Baxter Healthcare as Global Vice President for Medical and Scientific Affairs in the Renal business. During a nine-year tenure at Baxter, she held a number of senior leadership roles within the Renal as well as the Specialty Pharma therapeutic areas. Responsibilities included global medical affairs, clinical development, health economics, and scientific and clinical input for new product development and product life cycle management.

Board of Directors

Leslie Trigg

Chair and CEO

Read bio

Leslie has served as our Chief Executive Officer since November 2014 and was elected Chair in 2022. She joined the company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, she served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, including as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. She serves on the board of directors of the Medical Device Manufacturers Association. Leslie holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, UC Berkeley.

D. Keith Grossman

Lead Independent Director

Read bio

Keith has been a leader in the medical technology industry for more than 35 years. He is currently the Executive Chairman of Nevro Corporation (NVRO) where he was previously Chairman, President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, he served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG) where he co-led the medical device investment initiatives. Prior to TPG, he served as CEO, President and Director of Thoratec from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, he held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. In addition to serving as Executive Chairman of Nevro, he serves as Vice Chairman of Alcon Inc. (ALC), and he is a former member of the Board of Directors of ViewRay, Inc. (VRAY), Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.

Jim Hinrichs

Dir., Audit Committee Chair

Read bio

Jim has 30 years of financial leadership experience in large and small organizations within the healthcare industry. He currently serves as a Director of Orthofix Inc. (NASDAQ: OFIX), Integer Holdings (NYSE: ITGR), Acutus Medical (NASDAQ: AFIB) and Signifier Medical. Prior to these board roles, Jim served as Chief Financial Officer (CFO) of multiple companies: From 2018-2019, he was CFO of Cibus, a startup gene-editing company focused on the agriculture markets; From 2015 to 2017, he was Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company, until its sale to Abbott Labs for approximately $8 billion; From 2010 to 2015, he was CFO of CareFusion Corporation, a publicly traded medical technology company, until its sale to Becton Dickinson for approximately $12 billion. He previously served at Cardinal Health in various financial leadership positions including Executive Vice President and Corporate Controller of Cardinal Health and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University and is an inactive Chartered Financial Analyst (CFA).

Karen Drexler

Director

Read bio

Karen is a healthcare industry veteran with a focus on chronic disease management, data analytics, and home and acute user experience-focused machine learning. She has been an active board member for public and private medical device and diagnostics companies for over a decade, and currently sits on the board of ResMed (NYSE:RSMD), Tivic Health Systems (NASDAQ:TIVC), EBR Systems (ASX:EBR), VIDA Diagnostics, and Huma.AI. Most recently, she was CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. Previously, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. She started her career at LifeScan, where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson.

Patrick T. Hackett

Dir., Nominating & Corp. Gov. Committee Chair

Read bio

Patrick is a Special Limited Partner of Warburg Pincus (NYSE:WPCA). He joined Warburg Pincus in 1990 and in his 29 years at Warburg Pincus, he has focused on investments in the technology and health care services fields. Prior to joining Warburg Pincus, he was the Vice President of Cove Capital Associates, a private merchant banking partnership, and prior to that a partner with private equity firm, Acadia Partners. He is a Director of Intelligent Medical Objects, a private healthcare software company. In addition, he serves on the Board of Directors at Stamford Health System, a nonprofit community hospital in Connecticut. He graduated from the University of Pennsylvania with a B.A. in chemistry, and holds a B.S. in economics from the Wharton School at the University of Pennsylvania.

Katie Szyman

Director

Read bio

Katie has over 30 years of global medtech leadership experience, transforming businesses through the development of patient-focused innovations. She is currently Corporate Vice President and General Manager, Critical Care at Edwards Lifesciences (NYSE: EW) where she is responsible for the company’s critical care and vascular business. Prior to Edwards, she spent more than 20 years in senior corporate strategy and financial management roles at Medtronic (NYSE: MDT). She currently serves on the boards of Inari Medical Inc. (NASDAQ: NARI) and the American Heart Association of Orange County.

Andrea Saia

Director

Read bio

Andrea is an accomplished global business leader having focused her 40-year career building leading multinational brands in the consumer products and medical technology businesses with Novartis, Unilever, Revlon and Procter & Gamble. She currently serves on the boards of Align Technology (NASDAQ: ALGN) and Livanova plc (NASDAQ: LIVN). She also served on the board of Coca Cola Enterprises. Previously, she was Global Head of Vision Care for Alcon and CEO/President of Cibavision, a Novartis division.

Dale Jones

Dir., Compensation Committee Chair

Read bio

Dale is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking, before moving into executive search as a managing partner in the Atlanta office of Heidrick & Struggles International in 1999. In 2007, he relocated to Washington, D.C. to lead a philanthropic initiative, endowed by AOL founder Steve Case and his wife, Jean, that was dedicated to providing access to clean water in Africa. Mr. Jones returned to executive search in 2009, rejoining Heidrick & Struggles to serve as Vice Chairman and Partner of the CEO and Board Practice, where he consulted CEOs and corporate boards on human capital issues including recruiting, retention, succession planning, and corporate governance.

Learn more about opportunities at Outset.

Visit our careers page

About Us

Evolution of Outset

HD+ is officially funded

First human treatments on Tablo® in Mexico City

FDA clearance for acute and chronic use, and we gain a CE Mark

HD+ becomes Outset Medical

2nd generation of Tablo is initiated; home clinical trial begins

First use of Tablo in the acute setting at Cleveland Clinic

Tablo launches commercially

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief

FDA clearance for home use; Outset goes public, listed on NASDAQ

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

Leadership

Chair and CEO

Chief Financial Officer

Chief Commercial Officer

Chief Medical Officer

Chief People Officer

General Counsel

Chief Regulatory and Quality Officer

Chief Technology Officer

Advisors

Board of Directors

Learn more about opportunities at Outset.

1321-v2 (v2.0)

Tablo Coordinators Program

EMR Connect

Discover Dialysis

Vascular Access Program

Destination Home

Bridge Program

Tablo E-Learning

Service & Support

First human treatments on Tablo^® in Mexico City